TD Cowen analyst Boris Peaker lowered the firm’s price target on CTI BioPharma to $8 from $10 and keeps an Outperform rating on the shares. The analyst said we are updating our model and corresponding estimates as VONJO sales have been slower than initially anticipated.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTIC: